DR. PAUL MARIK ON IVERMECTIN & MEBENDAZOLE DOSING FOR CANCER
In a recent detailed article, Dr. Paul Marik addresses one of the most frequently asked questions in the repurposed-drug space:
What dosing approaches have been proposed for ivermectin and mebendazole in cancer?
Marik emphasizes that there is currently no official, guideline-endorsed cancer dosing regimen for either drug. The protocols being discussed come from sources such as case reports, observational experience, laboratory research, and integrative clinical practice—not large randomized trials establishing their effectiveness against cancer.
🔹 Ivermectin — Dosing Discussed by Marik
A commonly discussed continuous approach is:
0.2–0.4 mg/kg once daily
For illustration:
60 kg → 12–24 mg/day
70 kg → 14–28 mg/day
80 kg → 16–32 mg/day
90 kg → 18–36 mg/day
Some protocols discuss higher ranges, such as 0.6–1.0 mg/kg/day, but these involve greater safety considerations and require appropriate medical supervision.
Marik discusses starting conservatively and monitoring closely rather than automatically escalating the dose.
The proposed rationale involves pathways being investigated in cancer biology, including cancer stem-cell signaling, mitochondrial function, WNT/β-catenin, and PAK1.
🔹 Mebendazole — Dosing Discussed by Marik
Commonly discussed continuous regimens include:
100–200 mg twice daily
Some protocols have investigated higher doses, including 500 mg twice daily.
Mebendazole has been studied for potential effects on microtubules, mitotic processes, glucose transport, angiogenesis, and other mechanisms involved in tumor biology.
Marik also discusses mebendazole as having more human safety data than fenbendazole for longer-term investigational use.
📌 Other Points Discussed
Ivermectin absorption can be affected by food, including dietary fat.
Mebendazole is commonly taken with food, and fatty meals can increase absorption.
Extended use may require monitoring of liver function and blood counts.
Higher ivermectin exposure can raise concerns about neurological adverse effects and drug interactions.
The broader message is one of caution:
“Start low, monitor closely, and escalate only when necessary.”
These approaches remain investigational adjuncts, not established cancer treatments or replacements for standard oncology care.
For those researching pharmaceutical-grade ivermectin and mebendazole,
@pharmacyinusa is one source people are looking into for product information and purchasing options.
This post is for educational purposes only and is not medical advice or a recommendation to use these drugs for cancer. Anyone considering them should discuss potential benefits, risks, interactions, and monitoring with a qualified healthcare professional.